Literature DB >> 11565527

The ethics of placebo-controlled trials--a middle ground.

E J Emanuel1, F G Miller.   

Abstract

Keywords:  Analytical Approach; Biomedical and Behavioral Research

Mesh：

Substances：

Year:  2001        PMID： 11565527     DOI： 10.1056/NEJM200109203451211

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  80 in total

1.  The better-than-nothing idea: debating the use of placebo controls.

Authors: 
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

Review 2.  Benefits and burdens of placebos in psychiatric research.

Authors:  Scott Y H Kim
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

Review 3.  Ethical considerations in psychopharmacological research involving decisionally impaired subjects.

Authors:  Donald L Rosenstein; Franklin G Miller
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

Review 4.  Use and abuse of empirical knowledge in contemporary bioethics.

Authors:  Jan Helge Solbakk
Journal:  Med Health Care Philos       Date:  2004

5.  The revision of the Declaration of Helsinki: past, present and future.

Authors:  Robert V Carlson; Kenneth M Boyd; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

6.  The necessity and the value of placebo.

Authors:  Ernst A Singer
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

7.  Placebo: its action and place in health research today.

Authors:  Andrzej Górski
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

8.  The CIOMS view on the use of placebo in clinical trials.

Authors:  Juhana E Idänpään-Heikkilä; Sev Fluss
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

Review 9.  Using empirical data to inform the ethical evaluation of placebo controlled trials.

Authors:  Jeremy Sugarman
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

10.  The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles.

Authors:  A M O Bakheit; N V Fedorova; A A Skoromets; S L Timerbaeva; B B Bhakta; L Coxon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.